Truist raised the firm’s price target on Disc Medicine (IRON) to $114 from $86 and keeps a Buy rating on the shares. The firm is updating its model to incorporate Disc’s Q3 financial results, the full U.S. bitopertin opportunity in EPP, and an accelerated launch timeline following receipt of the FDA Commissioner’s priority review vouchers, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine: Strong Financial Position and Promising Product Pipeline with Bitopertin’s Billion-Dollar Potential
- Disc Medicine Advances Pipeline Amid Financial Growth
- Disc Medicine’s Promising Pipeline and Regulatory Advancements Justify Buy Rating
- Disc Medicine reports Q3 EPS ($1.77), consensus ($1.47)
- Disc Medicine resumed with a Buy at Stifel